UPDATE: Oxford-based Ochre Bio has closed a deal to the value of $1BN+ with European drugmaker Boehringer Ingelheim. In this latest deal, the EIT Health-supported start-up will investigate potential treatments that aim to harness the liver’s capacity to self-repair, in collaboration with EIT Health partner Boehringer Ingelheim.

🌟 Step into the realm of healthcare innovation with us in this captivating episode of Healthcare Disruptors! Join us as we explore the dynamic world of liver health innovation alongside Jack O'Meara, the CEO and co-founder of Ochre Bio.

💡 Ochre Bio stands at the forefront of revolutionary therapies designed to address the most critical issues in liver health. From enhancing donor liver supply to mitigating complications of cirrhosis, Ochre Bio is pioneering transformative solutions that promise to reshape the landscape of healthcare.

🚀 In this episode, Jack candidly shares his personal journey, motivations, and the challenges encountered while navigating the complex biotech arena. Delve into the inception of Ochre Bio, discover the hurdles overcome along the way, and gain invaluable insights into the realities of healthcare disruption.

💪 Don't miss out on this opportunity to gain deeper insights into the transformative potential of biotech entrepreneurship and the unwavering commitment to innovate for enhanced healthcare outcomes. Tune in and be inspired to join the movement toward a healthier future!

This podcast series is proudly presented by EIT Health Innovators Community. Join the movement today!

🔗 community.eithealth.eu 🔗